Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01463306 · ClinicalTrials.gov registry record · Phase 3
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
A Phase 3 study of Epilepsy, Partial Seizures and Epilepsy, Primary Generalized Tonic-Clonic Seizures, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 605
- Enrollment target
- 20
- Study locations
NCT01463306 is a Phase 3 study of Epilepsy, Partial Seizures and Epilepsy, Primary Generalized Tonic-Clonic Seizures that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 605 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT01463306, a Phase 3 study of Epilepsy, Partial Seizures and Epilepsy, Primary Generalized Tonic-Clonic Seizures, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 605 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seizures and pediatric and adult subjects 5 to 65 years of age with primary generalized tonic-clonic seizures. Pregabalin will be administered in equally divided daily doses for 1 year, in either capsule or liquid oral formulation.
Conditions Studied
Interventions
- DRUG Pregabalin
Study Locations (20)
Florida
- Axcess Medical Research - Loxahatchee Groves
- Laszlo J. Mate, M.D., P.A. - North Palm Beach
- Pediatric Epilepsy Center Of Central Florida - Orlando
- Pediatric Neurology, PA - Orlando
- Tallahassee Neurological Clinic - Tallahassee
- Pediatric Epilepsy and Neurology Specialists, PA - Tampa
Kentucky
- Kosair Children's Hospital - Louisville
- University of Louisville Physicians - Louisville
Ohio
- Akron Children's Hospital - Akron
- Ohio Clinical Research Partners, LLC - Canton
Pennsylvania
- The children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center - Pittsburgh
Texas
- Dallas Pediatric Neurology Associates - Dallas
- Road Runner Research, Ltd. - San Antonio
Arizona
- Center for Neurosciences - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- Children's Hospital Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 2012-02-21 |
| Est. Completion | 2019-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01463306
The ClinicalTrials.gov registry entry for NCT01463306 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 605 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsy, Partial Seizures appearing as the primary indexed condition, and to 1 intervention - of which Pregabalin is the first listed.
NCT01463306 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Kentucky, Ohio.
Frequently Asked Questions
What is clinical trial NCT01463306 about?
NCT01463306 is a clinical study titled "A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures". Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seizures and pediatric and adult subjects 5 to 65 years of age with primary generalized tonic-clonic sei...
What is the current status of trial NCT01463306?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 605 participants. The study started on 2012-02-21. Estimated completion is 2019-08-22.
What conditions does trial NCT01463306 study?
This clinical trial studies the following conditions: Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures.
What interventions are being tested in trial NCT01463306?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT01463306?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01463306 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Partial Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Epilepsy, Partial Seizures
All registered trials for this condition
Epilepsy, Primary Generalized Tonic-Clonic Seizures
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.